G
Graeme A. Macdonald
Researcher at University of Queensland
Publications - 155
Citations - 6335
Graeme A. Macdonald is an academic researcher from University of Queensland. The author has contributed to research in topics: Fatty liver & Steatosis. The author has an hindex of 34, co-authored 143 publications receiving 5775 citations. Previous affiliations of Graeme A. Macdonald include University of Illinois at Chicago & Translational Research Institute.
Papers
More filters
Journal ArticleDOI
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
Luke F. Hourigan,Graeme A. Macdonald,David M. Purdie,Vicki H. Whitehall,Claudia Shorthouse,Andrew D. Clouston,Elizabeth E. Powell +6 more
TL;DR: It is suggested that increasing body mass index has a role in the pathogenesis of steatosis in chronic hepatitis C and that Steatosis may contribute to fibrosis.
Journal ArticleDOI
Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
D. K. George,S. Goldwurm,Graeme A. Macdonald,L. L. Cowley,Neal I. Walker,Ward Pj,E C Jazwinska,L. W. Powell +7 more
TL;DR: The Cys282Tyr mutation is responsible for most of the mild iron overload found in NASH and thus has a significant association with hepatic damage in these patients, which cannot always be considered benign.
Journal ArticleDOI
Adiponectin--a key adipokine in the metabolic syndrome.
Jonathan P. Whitehead,Ayanthi A. Richards,Ingrid J. Hickman,Graeme A. Macdonald,Johannes B. Prins +4 more
TL;DR: Given the low levels of adiponectin in subjects with the metabolic syndrome, and the beneficial effect of the adipokine in animal studies, there is exciting potential for adiponECTin replacement therapy in insulin resistance and related disorders.
Journal ArticleDOI
Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C
Ingrid J. Hickman,Andrew D. Clouston,Graeme A. Macdonald,David M. Purdie,Johannes B. Prins,Susan Ash,J. R. Jonsson,Elizabeth E. Powell +7 more
TL;DR: Weight reduction in patients with chronic hepatitis C may be associated with a reduction in steatosis and abnormal liver enzymes and an improvement in fibrosis, despite the persistence of the virus.
Journal ArticleDOI
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
Veronique S. Chachay,Graeme A. Macdonald,Jennifer H. Martin,Jonathan P. Whitehead,Trisha O'Moore-Sullivan,Paul Lee,Michael E. Franklin,Kerenaftali Klein,Paul J. Taylor,Maree Ferguson,Jeff S. Coombes,Gethin P. Thomas,Gary Cowin,Carl M. J. Kirkpatrick,Johannes B. Prins,Ingrid J. Hickman +15 more
TL;DR: Eight weeks administration of resveratrol did not significantly improve any features of NAFLD, compared with placebo, but it increased hepatic stress, based on observed increases in levels of liver enzymes.